within Pharmacolibrary.Drugs.ATC.N;

model N06BA11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.22,
    Cl             = 2.9999999999999997e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00265,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06BA11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dexmethylphenidate is the d-threo-enantiomer of methylphenidate, a central nervous system stimulant used in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. It is approved and commonly prescribed for ADHD management due to its efficacy and tolerability.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after single-dose oral administration of immediate-release dexmethylphenidate tablets.</p><h4>References</h4><ol><li><p>Spencer, TJ, et al., &amp; Fischman, AJ (2012). Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. <i>The Journal of clinical psychiatry</i> 73(3) 346–352. DOI:<a href=\"https://doi.org/10.4088/JCP.10m06393\">10.4088/JCP.10m06393</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22154896/\">https://pubmed.ncbi.nlm.nih.gov/22154896</a></p></li><li><p>Braeckman, R, et al., &amp; Oh, C (2022). Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder. <i>Journal of child and adolescent psychopharmacology</i> 32(5) 288–295. DOI:<a href=\"https://doi.org/10.1089/cap.2022.0015\">10.1089/cap.2022.0015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35666231/\">https://pubmed.ncbi.nlm.nih.gov/35666231</a></p></li><li><p>McGough, JJ, et al., &amp; Suddath, R (2005). Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. <i>Expert review of neurotherapeutics</i> 5(4) 437–441. DOI:<a href=\"https://doi.org/10.1586/14737175.5.4.437\">10.1586/14737175.5.4.437</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16026226/\">https://pubmed.ncbi.nlm.nih.gov/16026226</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06BA11;
